Incyclix Bio, LLC (formerly Arc Therapeutics, LLC), a next-generation cell cycle control company, today announced the closing of a $30 million Series B financing led by new investor Boxer Capital. Additional new investor RA Capital Management also participated in the round, along with existing investor Eshelman Ventures. Sid Subramony, Ph.D., Vice President of Boxer Capital, will join the Company’s board of directors. Nathaniel Brooks Horwitz, Principal of RA Capital Management, will join Incyclix Bio as a board observer.

Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers.

Incyclix Bio Announces $30 Million Series B Financing Led By Boxer Capital

Description

Company Information

Funding Insights

Incyclix Bio Announces $30 Million Series B Financing Led By Boxer Capital

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information